# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
SEC
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and announc...
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and raises the price target fr...
Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for ...